Second-line chemotherapy in advanced biliary cancer: the present now will later be past
Ann Oncol
.
2014 Dec;25(12):2443-2444.
doi: 10.1093/annonc/mdu379.
Epub 2014 Aug 13.
Authors
C Vivaldi
1
,
L Fornaro
2
,
S Cereda
3
,
G Aprile
4
,
D Santini
5
,
N Silvestris
6
,
S Lonardi
7
,
F Leone
8
,
M Milella
9
,
G Brandi
10
,
E Vasile
11
Affiliations
1
Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, University of Pisa, Pisa.
2
Unit of Medical Oncology, Azienda USL2 Lucca, Lucca.
3
Department of Medical Oncology, San Raffaele Scientific Institute, Milan.
4
Department of Oncology, University and General Hospital, Udine.
5
Department of Medical Oncology, University Campus Bio-Medico, Rome.
6
Unit of Medical Oncology, National Cancer Institute Giovanni Paolo II, Bari.
7
Unit of Medical Oncology 1, Istituto Oncologico Veneto, IRCCS, Padova.
8
Unit of Medical Oncology, Institute for Cancer Research and Treatment IRCCS Candiolo, University of Torino, Turin.
9
Medical Oncology A, Regina Elena National Cancer Institute, Rome.
10
Unit of Medical Oncology, Sant'Orsola Malpighi Hospital, University of Bologna, Bologna, Italy.
11
Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, University of Pisa, Pisa;. Electronic address: envasile@tin.it.
PMID:
25122694
DOI:
10.1093/annonc/mdu379
No abstract available
Publication types
Letter
Comment
MeSH terms
Antineoplastic Agents / therapeutic use*
Biliary Tract Neoplasms / drug therapy*
Humans
Substances
Antineoplastic Agents